Background: Presence of blood brain barrier is one of the major hurdle in drug delivery to
brain for the treatment of neurological diseases. Alternative and more effective drug delivery approaches
have been investigated for the drug targeting to brain in therapeutic range.
Objective: The present investigation was carried out to improve the galantamine bioavailability in brain
by intranasal drug delivery through thiolated chitosan nanoparticles and compared to nasal and oral
delivery of its solution using pharmacodynamic activity as well as biochemical estimation.
Methods: Thiolated chitosan (modified) nanoparticles were fabricated using modified ionic gelation
method and intranasal delivery is evaluated by reversal of scopolamine induced amnesia and biochemical
estimation of acetylcholinesterase activity in Swiss albino mice brain. Scopolamine (0.4 mg/kg, i.p.)
was used to induce amnesia. Piracetam (400mg/kg, i.p.) was used as positive control. Mice were treated
with galantamine solution (4mg/kg) by oral and nasal route and formulated galantamine nanoparticles
(equivalent to 4mg/kg) by intranasal administration for 7 successive days and the results were compared
Results: Intranasal delivery of galantamine loaded thiolated chitosan nanoparticles was found significant
(p<0.05) as compared to oral and nasal administration of its solution, by pharmacodynamic study
and biochemical estimation of acetylcholinesterase activity in Swiss albino mice brain.
Conclusion: Significant recovery in amnesia induced mice model by intranasal administration of galantamine
loaded thiolated chitosan nanoparticles established the relevance of nose to brain delivery over
the conventional oral therapies for the treatment of Alzheimer’s disease.